Effect of vitamin D on HEL leukemia cell line
Albanyan, Omar Mohammed
MetadataShow full item record
Leukemia is the most common malignant disease of the hematopoietic system. It is defined as uncontrolled proliferation of neoplastic hematopoietic precursor cells and impaired production of normal cells. Acute myeloid leukemia (AML) is the most common type of leukemia in adults with the lowest survival rate of all forms. Current therapy for AML has harsh side effects and often is not curative. Vitamin D is a fat-soluble vitamin that functions mainly in calcium hemostasis. Recent discoveries of the biochemical targets , vitamin D receptors (VDR), were discovered in lymphoid cells and in the hematopoietic system. The epidemiology of vitamin D levels has not been studied heavily in AML as compared to solid tumors. Nonetheless, some studies showed an association between vitamin D levels and AML diagnosis and prognosis. In this study, the effect of vitamin D and the anti-leukemic chemotherapy drug, cytarabine (Ara-C) on the viability of a human AML cell line (Human Erythroleukemia (HEL)) was assessed. HEL cells were co-cultured with HS-5 (human stromal cells) to mimick the bone marrow microenvironment, and treated with vitamin D alone or in combination with Ara-C using two different doses and schedules. Our results show that treating HEL cells with a bolus dose of vitamin D has no effect on viability compared to no treatment. Treating HEL cells with a bolus dose of vitamin D and Ara-C has no effect on viability compared to treatment with with Ara-C or vitamin D alone. Treating HEL cells with multiple doses of vitamin D alone or in combination with Ara-C showed similar results to single dose schedule with no effect on viability compared to no treatmen. In conclusion, adding vitamin D did not enhance the antitumor effect of Ara-C on HEL cells.